| Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer A Alcaraz-Sanabria, C Nieto-Jimenez, V Corrales-Sanchez, ... Molecular cancer therapeutics 16 (11), 2552-2562, 2017 | 47 | 2017 |
| Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors C Nieto-Jiménez, A Alcaraz-Sanabria, J Pérez-Peña, V Corrales-Sánchez, ... Oncotarget 8 (12), 19478, 2017 | 23 | 2017 |
| Genomic signatures of immune activation predict outcome in advanced stages of ovarian cancer and basal-like breast tumors A Alcaraz-Sanabria, M Baliu-Piqué, C Saiz-Ladera, K Rojas, A Manzano, ... Frontiers in Oncology 9, 1486, 2020 | 22 | 2020 |
| In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases A Ocaña, J Pérez-Peña, A Alcaraz-Sanabria, V Sánchez-Corrales, ... Oncotarget 7 (16), 22865, 2016 | 22 | 2016 |
| Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors J Pérez-Peña, A Alcaraz-Sanabria, C Nieto-Jiménez, R Páez, ... Oncotarget 8 (13), 21733, 2017 | 17 | 2017 |
| DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer C Nieto-Jiménez, A Alcaraz-Sanabria, R Páez, J Pérez-Peña, ... Oncotarget 8 (38), 62834, 2017 | 15 | 2017 |
| Mapping of genomic vulnerabilities in the post-translational ubiquitination, SUMOylation and neddylation machinery in breast cancer J Fuentes-Antrás, AL Alcaraz-Sanabria, EC Morafraile, ... Cancers 13 (4), 833, 2021 | 14 | 2021 |
| Transcriptome evolution from breast epithelial cells to basal-like tumors G Santpere, A Alcaráz-Sanabria, V Corrales-Sánchez, A Pandiella, ... Oncotarget 9 (1), 453, 2018 | 14 | 2018 |
| Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates A Alcaraz-Sanabria, E Cabañas Morafraile, G Fernández-Hinojal, ... Frontiers in Immunology 12, 786069, 2022 | 9 | 2022 |
| Checkpoint kinase 1 pharmacological inhibition synergizes with DNA-damaging agents and overcomes platinum resistance in basal-like breast cancer C Nieto-Jimenez, A Alcaraz-Sanabria, S Martinez-Canales, ... International Journal of Molecular Sciences 21 (23), 9034, 2020 | 7 | 2020 |
| Treatment-related side effects as predictors of efficacy of check-point inhibitors (CPIs). RM Prince, L DÃez, A Alcaraz-Sanabria, JL Ethier, A Ocana, B Seruga, ... Journal of Clinical Oncology 34 (15_suppl), 3062-3062, 2016 | 1 | 2016 |
| TACkling Cancer by Targeting Selective Protein Degradation MM Noblejas-López, D Tébar-García, R López-Rosa, A Alcaraz-Sanabria, ... Pharmaceutics 15 (10), 2442, 2023 | | 2023 |
| DataSheet_2_Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p. G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates. pdf A Alcaraz-Sanabria, E Cabañas, G Fernández-Hinojal, G Velasco, ... Figshare, 2022 | | 2022 |
| Pharmacologic screening identifies synthetic lethality interactions with Chk1 inhibitors in basal-like breast and ovarian cancer EM Galan-Moya, A Alcaraz-Sanabria, C Nieto-Jimenez, ... Cancer Research 78 (13_Supplement), 1608-1608, 2018 | | 2018 |
